TNF-alpha inhibitors for psoriatic arthritis

Golicki, Dominik; Macioch, T.; Niewada, Maciej; Jakubczyk, Michał; Tłustochowicz, Małgorzata; Owczarek, Witold; Tłustochowicz, Witold

doi:10.1002/14651858.cd007940

Cited by 3 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor necrosis factor alpha (TNF‐α) inhibitors have revolutionized the treatment of many immune‐related chronic inflammatory diseases such as rheumatoid arthritis (RA), Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and ulcerative colitis . These agents bind to TNF‐α, preventing it from interacting with the TNF receptor.…”

mentioning

confidence: 99%

Sinusitis in patients on tumor necrosis factor alpha inhibitors

Wang

Honeybrook

Chapurin

et al. 2016

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background Tumor necrosis factor alpha (TNF-α) inhibitors have revolutionized treatment of many inflammatory diseases. Sinusitis after initiation of TNF-α inhibitors has been observed, but has not been well described in the literature. We aim to characterize the clinical features of sinusitis in patients on anti-TNF-α therapy. Methods This is a retrospective chart review of 28 patients on a TNF-α inhibitor diagnosed with sinusitis by otolaryngologists at Duke University. Patient demographics, sinusitis characteristics, and treatment course were studied by chart review. Results The prevalence of sinusitis diagnosed and treated by an otolaryngologist was less than 1%. Of the 28 patients studied, 12 (42.9%) had a history of preexisting sinusitis and 16 (57.1%) had new-onset sinusitis. 71.4% were diagnosed with chronic rhinosinusitis without polyps (CRSsNP), with disease mainly involving the maxillary and ethmoid sinuses. No patients had major extrasinus complications or required hospital admission or intravenous (IV) antibiotics. 35.7% (n =10), including 44% (7/16) of new-onset patients required a surgical intervention after initiating anti-TNF therapy. 14.3% (n = 4) of the cohort had improvement in sinonasal symptoms after stopping, changing, or holding doses of the TNF-α inhibitor. Conclusion Anti-TNF-α therapy can be associated with new-onset sinusitis, mainly CRSsNP. Overall, the percentage of patients on a TNF-α inhibitor seeking consultation from an otolaryngologist is low. While some patients with new-onset sinusitis will require surgery, modification of anti-TNF-α therapy should be considered as an option in the medical management of these patients.

show abstract

mentioning

confidence: 99%

Sinusitis in patients on tumor necrosis factor alpha inhibitors

Wang

Honeybrook

Chapurin

et al. 2016

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

Adverse effects of biologics: a network meta-analysis and Cochrane overview

Singh

Wells

Christensen

et al. 2010

Cochrane Database of Systematic Reviews

345

354

View full text Add to dashboard Cite

Adverse effects of biologics: a network meta-analysis and Cochrane overview

Singh

Wells

Christensen

et al. 2011

Cochrane Database of Systematic Reviews

487

197

View full text Add to dashboard Cite

To compare the potential adverse e ects of tumor necrosis factor inhibitor (adalimumab, certolizumab, etanercept, golimumab, infliximab), interleukin (IL)-1 antagonist (anakinra), IL-6 antagonist (tocilizumab), anti-CD28 (abatacept), and anti-B cell (rituximab) therapy in patients with any disease condition except human immunodeficiency disease (HIV/AIDS). Methods Randomized controlled trials (RCTs), controlled clinical trials (CCTs) and open-label extension (OLE) studies that studied one of the nine biologics for use in any indication (with the exception of HIV/AIDS) and that reported our pre-specified adverse outcomes (serious adverse events (SAEs), withdrawals due to adverse events (AEs), total AEs, serious infections; specific AEs, namely, tuberculosis (TB) reactivation, lymphoma and congestive heart failure) were considered for inclusion. We searched The Cochrane Library, MEDLINE, and EMBASE (to January 2010). Identifying search results and data extraction were performed independently and in duplicate. For the network metaanalysis, we performed both Bayesian mixed-treatment comparison models and arm-based generalized linear mixed models. Main results We included 160 RCTs with 48,676 participants and 46 extension studies with 11,954 participants. The median duration of RCTs was six months and 13 months for OLEs. Data were limited for TB reactivation, lymphoma, and congestive heart failure. Using standard dose, compared with control, biologics as a group were associated with a statistically significant higher rate of total AEs (odds ratio (OR) 1.28, 95% credible interval (CI) 1.09 to 1.50; number needed to treat to harm (NNTH) = 22, 95% confidence interval (CI) 14 to 60), withdrawals due to AEs (

show abstract

TNF-alpha inhibitors for psoriatic arthritis

Cited by 3 publications

References 43 publications

Sinusitis in patients on tumor necrosis factor alpha inhibitors

Sinusitis in patients on tumor necrosis factor alpha inhibitors

Adverse effects of biologics: a network meta-analysis and Cochrane overview

Adverse effects of biologics: a network meta-analysis and Cochrane overview

Contact Info

Product

Resources

About